Results 181 to 190 of about 8,212 (230)
Research Trends and Emerging Frontiers in Proteolysis Targeting Chimeras (PROTACs): A Bibliometric Analysis of 2630 Publications (2001-2025). [PDF]
Pharmaceuticals (Basel)Su G, Wang Y, Yao L.
europepmc +1 more source
AI-Driven Multi-Omics Integration of Synthetic Colon Adenocarcinoma for Cluster-Guided PROTAC Candidate Design Targeting KRASG12D. [PDF]
Int J Mol SciElamin KM, Elbashir SMI, Adam I.
europepmc +1 more source
FDA Approval of the First-Ever PROTAC: Vepdegestrant (ARV-471) Marks a New Era in Targeted Protein Degradation. [PDF]
J Med ChemKumar A, Ali S, Shen Q, Zhou J.
europepmc +1 more source
Targeted Protein Degradation Strategies in DNA Virus Research. [PDF]
VirusesLam M, Hill C, Thornburg E, DeSmet M.
europepmc +1 more source
Development of Trivalent PROTACs Based on BRD4-targeting PROTACs
Development of Trivalent PROTACs Based on BRD4-targeting PROTACsopenaire +1 more source
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Frontiers in Pharmacology, 2021 Proteolysis targeting chimeric (PROTAC) technology is an effective endogenous protein degradation tool developed in recent years that can ubiquitinate the target proteins through the ubiquitin-proteasome system (UPS) to achieve an effect on tumor growth.
Jinyun Dong +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The application of PROTAC in HDAC
European Journal of Medicinal Chemistry, 2023Inducing protein degradation by proteolysis targeting chimera (PROTAC) has provided great opportunities for scientific research and industrial applications. Histone deacetylase (HDAC)-PROTAC has been widely developed since the first report of its ability to induce the degradation of SIRT2 in 2017.
Shaoting Chen +7 more
openaire +2 more sources